Delivery Order SPE2DB22D2006-SPE2DB25FV9ZC

Award Date 4/14/25
Potential Completion Date 4/15/25
Potential Value $12K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,436.88 firm fixed-price delivery order is for RESTASIS 0.05% eye emulsion 30-count packages, with a completion date of December 4, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, with a ceiling value of $1,494.15, is a delivery order for RESTASIS 0.05% eye emulsion products. The contract has a firm-fixed price pricing type and an ultimate completion date of March 8, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,424.90, is a delivery order for the supply of RESTASIS 0.05% eye emulsion. The contract has an ultimate completion date of December 6, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $7,733.01, is for a delivery order of RESTASIS 0.05% eye emulsion with an ultimate completion date of November 26, 2024. The contract is a firm fixed-price agreement with no set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $38,052.66 firm-fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The contract has an ultimate completion date of June 30, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,280.21 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty ophthalmic medication. The contract has a completion date of June 3, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty ophthalmic medication, with a ceiling value of $19,553.81. This is a delivery order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA, valued at $999,999,999 and running through November...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,448.72 firm fixed-price delivery order is for the supply of 4568058105 - RESTASIS 0.05% EYE EMULSION 60S, a prescription eye medication. The contract has an ultimate completion date of April 29, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,117.68 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty ophthalmic medication. The contract has an ultimate completion date of December 30, 2024 and was awarded on December 27, 2024. It is not designated as a set-aside contract. AmerisourceBergen holds a significant...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $3,983.27 firm-fixed-price delivery order contract is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical division. This IDC serves as a primary vehicle for providing a...
  • SPE2DB22D2006
    Indefinite Delivery Contract
  • SPE2DB22D2006-SPE2DB25FV9ZC
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,528.16, is for the delivery of RESTASIS 0.05% eye emulsion. This is a firm fixed-price delivery order contract with an ultimate completion date of April 15, 2025.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains.

The contract award does not have a set-aside designation, indicating open competition. This contract supports the healthcare needs of military personnel, veterans, and other federal beneficiaries through a streamlined, comprehensive contracting mechanism.

Generated 7/14/25, 10:59 AM